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Every cancer treatment, irrespective of its clinical effectiveness, has an impact on patients’ quality of life (QoL). Even
recently developed targeted therapies might have side effects and significantly impact patients’ QoL. Thus,
understanding the advantages and disadvantages of different treatments from the patient’s standpoint has become
a must in clinical research and is highly valued by major stakeholders. Thousands of cancer patients are enrolled
into randomized controlled trials (RCTs) each year and many complete patient-reported outcome (PRO) instruments
to obtain patient-centered information as part of the assessment of the overall effectiveness of the new therapy.
Some of these RCTs have generated high quality PRO evidence forming the basis for approval (or support to
approval) of drugs by the US Food and Drug Administration. However, a consistent strategy to determine the
quality of patient centered evidence presented in RCTs has until recently been lacking. One of the fundamental
questions when including PROs in clinical research revolves around methodological robustness and consistency of
outcome reporting. Cancer patients, physicians and healthcare system stakeholders need to rely on solid
information to make the best possible choice regarding treatment. Therefore generating high-quality findings from
PRO assessment in cancer trials is of paramount importance. In an effort to improve quality of PRO assessment and
reporting in the near future, the Patient-Reported Outcome Measurements Over Time In ONcology (PROMOTION)
Registry was developed. The scope of this Registry is to identify, track, analyse, and store information on all cancer
RCTs that have included PROs, and assess the quality of their PRO assessments.
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Cancer is now an increasingly common diagnosis world-
wide as population longevity increases. Recent data from
the International Agency for Cancer research (IARC) indi-
cate approximately 14.1 million new cancer cases in 2012,
a rise of more than 10% compared to 2008 (12.7 million
cases), and further projections suggest an increase to 19.3
million new cancer cases per year by 2025 [1]. Therefore,
understanding how cancer and its treatment impact on
each aspect of a patient’s life is critical and remains a
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unless otherwise stated.Every cancer treatment, irrespective of its clinical
effectiveness, has an impact on patients’ quality of life
(QoL). Standard treatments have traditionally included
chemotherapy, radiotherapy and surgery or a combin-
ation of these. In recent years, anticancer-targeted
therapies have been developed for some cancers, and
very often these greatly contribute to improving both
survival and QoL [2,3]. Nonetheless, even targeted
therapies might have side effects and significantly impact
patients’ QoL [4]. Thus, understanding the advantages
and disadvantages (pro and cons) of different treat-
ments from the patient’s standpoint has become a must
in clinical research and is highly valued by major stake-
holders [5].l Ltd. This is an Open Access article distributed under the terms of the Creative
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Randomized controlled trials (RCTs), play a key role in
cancer research as they provide the best methodology to
evaluate treatments and inform health policy and practice.
Within RCTs in oncology, it is now commonplace to make
assessment of patient-reported outcomes (PROs). Thou-
sands of cancer patients are enrolled into RCTs each year
and many complete relevant PRO instruments to obtain
patient-centered information as part of the assessment of
the overall effectiveness of the new therapy. A number of
these RCTs have generated high quality PRO evidence and
some of these have also formed the basis for approval (or
support to approval) of drugs by the US Food and Drug
Administration (FDA) by showing better PROs with a
given treatment. Examples of this include mitoxantrone
for prostate cancer patients and imatinib for patients with
chronic myeloid leukemia [3,6]. However, it should be
noted that methodological drawbacks in the design and
reporting of PROs have often limited the use of PRO data
in approval of drugs [7].
However, a consistent strategy to determine the quality
of patient centered evidence presented in RCTs has until
recently been lacking, but is vital to clinicians as PRO
data from RCTs may directly inform patients and practi-
tioners regarding the effects of a treatment, or may in-
directly influence clinical practice by incorporation into
relevant guidelines [8]. One of the fundamental questions
when including PROs in clinical research revolves around
methodological robustness and consistency of outcome
reporting. There are a number of well known challenges,
for example, to PRO data collection, appropriate timing
of assessment, adequate statistical analysis and outcome
interpretation [9,10]. In addition, the choice of the PRO
questionnaire is also a fundamental aspect to be consid-
ered; the questionnaire should be relevant for the specific
research question, and with solid psychometric character-
istics (e.g., valid, reliable and responsive to health changes).
Cancer patients, physicians and healthcare system stake-
holders need to rely on solid information to make the best
possible choice regarding treatment. Therefore generating
high-quality findings from PRO assessment in cancer trials
is of paramount importance. Poorly designed or reported
PROs assessment is likely to hamper the critical appraisal
of results and limit the knowledge transfer from research
settings to clinical practice.
The European Organisation for Research and Treatment
of Cancer (EORTC) Quality of Life Group (QLG) has
pioneered the field of methodological research in this
area by developing and validating an international port-
folio of measures to be used in RCTs in oncology [11].
The EORTC has led on several published reviews of
PRO in RCTs, showing that the application of PROs in
many trials was plagued by important methodological
drawbacks, limiting the generalizability of the results[12-15]. In response to these findings the EORTC raised
the need to establish international standards for QoL
assessment in cancer clinical trials [16] and made sig-
nificant efforts to define basic minimum criteria to
guide investigators when reporting HRQOL from can-
cer RCTs [17]. Further international initiatives have
subsequently been launched to increase the quality of
PRO assessment in clinical trials, including guidance
from the International Society for Quality of Life Re-
search (ISOQOL) [18]. The ISOQoL guidance is of
particular value as it formed the basis for the develop-
ment of the recently issued CONSORT PRO recom-
mendations [19].
In an effort to improve quality of PRO assessment and
reporting in the near future, the EORTC QLG recently
contributed to devise the Patient-Reported Outcome
Measurements Over Time In ONcology (PROMOTION)
Registry (http://promotion.gimema.it). This is also co-
financed by the Italian Group for Adult Hematologic
Diseases (GIMEMA). The broad scope of this Registry is
to identify, track, analyse, and store information on all
cancer RCTs that have included PROs, and assess the
quality of their PRO assessments. This work is being
performed using a common set of criteria across all
cancer disease sites, thus allowing comparisons across
all cancer areas.Overview on registry content and type of information
included
The database stores information stemming from published
RCTs that enrolled at least 50 patients overall, that report
PROs, and that have been published since 2004. To date,
nearly 600 studies in a wide range of cancer populations
have been identified, analyzed and electronically archived.
Data on more than 50 different items have been extracted
from each eligible study.
This information is categorized into three broad
groups, that is: 1) Study characteristics, including sum-
mary of clinical and PRO results; 2) PRO methodology,
based on the recently published recommendations by
ISOQOL [18] and the CONSORT PRO group [19] and
3) Risk of bias assessed using the Cochrane Risk of Bias
tool. We acknowledge the evaluation of this latter aspect
might be challenging by just reading the publication of
study results, and inspection of full study protocol would
be valuable. In any case, this tool specifically evaluates the
adequacy of sequence generation, allocation concealment,
blinding of participant/personnel, incomplete outcome
data reporting, blinding of outcome assessment, selective
outcome reporting and other possible sources of bias
for each RCT [20]. For descriptive purposes, in Table 1
we report a summary of some of the key data collected
in the registry (Table 1).
Table 1 Descriptive summary of some key data contained in the PROMOTION Registry (http://promotion.gimema.it)
Basic Study
Characteristics
Name of Cooperative Group/s leading the study (if any)
Study location
Industry support
Primary endpoint/s
Difference between treatment arms in the primary endpoint (if any)
Age of patients
Gender of patients
Disease stage
Overall trial sample size
PRO sample size
PRO instrument/s used
Summary of PRO results
If statistically significant PRO difference exists, details of the domain/s of interest should be reported (e.g. symptoms
only, functional aspects, global quality of life)
Summary of main clinical (other than PRO) results
PRO Methodology and
Analysis
PRO identification in the abstract
Statement of PRO hypothesis and its PRO domain
Description of the mode of administration of the PRO tool and the methods of collecting data
Electronic mode of PRO administration
Description of the rationale for choice of the PRO instrument
Citation of evidence of PRO instrument validity and reliability
Description of the intended PRO data collection
Statement of the status of PRO as either a primary or secondary outcome
Statement of the magnitude of the effect size (for statistically significant PRO results)
Description of statistical approaches for dealing with missing data
Statement of the extent of missing data
Flow diagram or description of the allocation of participants and those lost to follow-up for PROs specifically
Statement of the reasons for missing data
Description of the study patients’ characteristics including baseline PRO scores
Reporting of PRO outcomes in a graphical format
Discussion of the limitations of the PRO components of the trial
Discussion of the limitations of the clinical significance of the PRO findings
Methodology used to assess clinical significance
Discussion of the PRO results in the context of the other clinical trial outcomes
Study Validity
Selection bias
Performance bias
Detection bias
Attrition bias
Reporting bias
Abbreviation: PRO (Patient-Reported Outcome).
Legend: the following aspects are reported for descriptive purposes only. This is not a comprehensive list of all data contained in the PROMOTION Registry.
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All published RCTs meeting the inclusion criteria are
identified by electronic searching of PubMed/Medline,
the Cochrane library, PsycINFO and PsycARTICLES.Hand searching of the bibliographies of eligible articles
are also performed.
After eligibility of articles for inclusion is confirmed, a
minimum of two trained reviewers (who are also study
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extract pre-specified information. Every reviewer has a
personal password to access the online system to complete
the electronic-data extraction form (eDEF), details of
which have been reported previously [21]. This ap-
proach allows a double blind data entry procedure to
ensure accuracy and validity of data entry into the
Registry. Discrepancies in the independent evaluations
are recorded and a discrepancy form automatically gen-
erated by the system. Discrepancies are discussed by
the two reviewers and resolved by them with a third re-
viewer reconciling any continuing discrepancies. After
the review team reach consensus for all items the final
eDEF for the RCT is locked, validated and imported in
the Registry for research use.Future work and value to the international community
The methodological challenge of incorporating PROs into
cancer RCTs is frequently cited as a major limiting fac-
tor for their use. However, through the PROMOTION
Registry data we have begun to show that PRO meth-
odological quality has improved over time in RCTs in
prostate disease, suggesting that the methodological
challenges related to PRO logistics, design and analyses
are no longer insurmountable [21].
Work continues within the PROMOTION Registry
team to determine if this is also the case for other cancer
sites, and to identify key areas where PRO methodology
remains poor in cancer RCTs and needs to be addressed
to facilitate the translation of PRO findings from research
to clinical practice.
The PROMOTION Registry (http://promotion.gimema.it)
is now an extensive source of information for all investiga-
tors involved in PROs related cancer research and will
continue to be regularly updated. Data and information
contained in the registry can be used to address specific
clinical or more methodological research questions. We
welcome research proposals from other investigators and
research groups (not only from GIMEMA and the EORTC
QLG) to collaborate with the international PROMOTION
team in the effort to drive PROs into clinical practice and
better inform healthcare decisions.Competing interests
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